# US 2004/0018150 A1 · Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018150 A1
- Document ID: US20040018150A1
- Status: Published application
- Kind: A1
- Application number: 10/333,107
- Filed: 2003-01-14
- Published: 2004-01-29
- Earliest claimed: 2003-01-14
- Inventors: Mark W. Becker; Harlan H. Chapman; Tomas Cihlar; Eugene J. Eisenberg; Gong-Xi He; Michael R. Kernan; William A. Lee; Ernest J. Prisbe; John C. Rohloff; Mark L. Sparacino
- Web page: https://patentgrep.com/patent/US20040018150A1

## CPC

- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07F 9/65616: {containing the ring system [IMAGE cpc-sch-C07F-1006.gif] having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs}
- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C12Q 1/18: Testing for antimicrobial activity of a material
- G01N 33/5011: {for testing antineoplastic activity}
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein.

## Claims

### Claim 1

A screening method for identifying a methoxyphosphonate nucleotide analogue prodrug conferring enhanced activity in a target tissue comprising:
(a) providing at least one of said prodrugs;
(b) selecting at least one therapeutic target tissue and at least one non-target tissue;
(c) administering the prodrug to the target tissue and to said at least one non-target tissue; and
(d) determining the relative activity conferred by the prodrug in the tissues in step (c).

### Claim 2 (depends on 1)

The method of claim 1 wherein the activity is antiviral activity or antitumor activity.

### Claim 3 (depends on 2)

The method of claim 2 wherein the activity is antiviral activity.

### Claim 4 (depends on 3)

The method of claim 3 wherein the activity is anti-HIV or anti-HBV activity.

### Claim 5 (depends on 1)

The method of claim 1 wherein the prodrug is a prodrug of PMPA or PMEA.

### Claim 6 (depends on 5)

The method of claim 5 wherein the prodrug is a phosphonoamidate, phosphonoester or mixed phosphonoamidate/phosphonoester.

### Claim 7 (depends on 6)

The method of claim 6 wherein the amidate is an amino acid amidate.

### Claim 8 (depends on 6)

The method of claim 6 wherein the ester is an aryl ester.

### Claim 9 (depends on 1)

The method of claim 1 further comprising selecting a prodrug having a relative activity in the target tissue that is greater than 10 times that of the non-target tissue.

### Claim 10 (depends on 1)

The method of claim 1 wherein the target and non-target tissue are in an animal, the prodrug is administered to the animal and the relative activity is determined by analysis of the animal tissues after administration of the prodrug.

### Claim 11 (depends on 1)

The method of claim 1 wherein activity in the target and non-target tissues is determined by assaying the amount of at least one metabolite of the prodrug in the tissues.

### Claim 12 (depends on 12)

The method of claim 12 wherein the metabolite is the parental drug.

### Claim 13 (depends on 12)

The method of claim 12 wherein the metabolite is the diphosphate of the parental drug.

### Claim 14 (depends on 1)

The method of claim 1 wherein the target tissue is virally infected tissue and the non-target tissue is the same tissue which is not virally infected.

### Claim 15 (depends on 1)

The method of claim 1 wherein the target tissue is lymphoid tissue and the activity is anti-HIV activity.

### Claim 16 (depends on 1)

The method of claim 1 wherein the target tissue is liver and the activity is anti-HBV activity.

### Claim 17 (depends on 1)

The method of claim 1 wherein the target tissue is hematological and the activity is antitumor activity.

### Claim 18 (depends on 1)

The method of claim 1 wherein the target tissue is malignant and the non-target tissue is the same tissue but non-malignant.

### Claim 19

A compound having the structure (1)
33
where Ra is H or methyl,
and chirally enriched compositions thereof, salts, their free base and solvates thereof.

### Claim 20

A compound having the structure (2)
34
and its enriched diasteromers, salts, free base and solvates.

### Claim 21

A diastereomerically enriched compound having the structure (3)
35
which is substantially free of the diastereomer (4)
36
wherein
R1 is an oxyester which is hydrolyzable in vivo, or hydroxyl;
B is a heterocyclic base;
R7 is hydroxyl, or the residue of an amino acid bonded to the P atom through an amino group of the amino acid and having each carboxy substituent of the amino acid optionally esterified, but not both of R1 and R2 are hydroxyl;
E is —(CH2)2—, —CH(CH3)CH2—, —CH(CH2F)CH2—, —CH(CH2OH)CH2—, —CH(CH═CH2)CH2-—, —CH(C≡CH)CH2—, —CH(CH2N3)CH2—,
37
—CH(R6)OCH(R6′)—, —CH(R9)CH2O— or —CH(R8)O—, wherein the right hand bond is linked to the heterocyclic base;
the broken line represents an optional double bond;
R4 and R5 are independently hydrogen, hydroxy, halo, amino or a substituent having 1-5 carbon atoms selected from acyloxy, alkyoxy, alkylthio, alkylamino and dialkylamino;
R6 and R6′ are independently H, C1-C6 alkyl, C1-C6 hydroxyalkyl, or C2-C7 alkanoyl;
R7 is independently H, C1-C6 alkyl, or are taken together to form —O— or —CH2—;
R8 is H, C1-C6 alkyl, C1-C6 hydroxyalkyl or C1-C6 haloalkyl; and
R9 is H, hydroxymethyl or acyloxymethyl;
and their salts, free base, and solvates.

### Claim 22

A diastereomerically enriched compound having the structure (5a)
38
which is substantially free of diastereomer (5b)
39
wherein
R5 is methyl or hydrogen;
R6 independently is H, alkyl, alkenyl, alkynyl, aryl or arylalkyl, or R6 independently is alkyl, alkenyl, alkynyl, aryl or arylalkyl which is substituted with from 1 to 3 substituents selected from alkylamino, alkylaminoalkyl, dialkylaminoalkyl, dialkylamino, hydroxyl, oxo, halo, amino, alkylthio, alkoxy, alkoxyalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylalkoxyalkyl, haloalkyl, nitro, nitroalkyl, azido, azidoalkyl, alkylacyl, alkylacylalkyl, carboxyl, or alkylacylamino;
R7 is the side chain of any naturally-occurring or pharmaceutically acceptable amino acid and which, if the side chain comprises carboxyl, the carboxyl group is optionally esterified with an alkyl or aryl group;
R11 is amino, alkylamino, oxo, or dialkylamino; and
R12 is amino or H;
and it salts, tautomers, free base and solvates.

### Claim 23

A compound of structure (6)
40
and its salts and solvates.

### Claim 24

A compound of structure (7)
41

### Claim 25 (depends on 19, 20, 21, 22, 23, 24)

A composition comprising a compound of any of claims 19-24 and a pharmaceutically effective excipient.

### Claim 26 (depends on 25)

The composition of claim 25 wherein the excipient is a gel.

### Claim 27 (depends on 25)

The composition of claim 25 which is suitable for topical administration.

### Claim 28 (depends on 19, 20, 21, 22, 23, 24)

A method for antiviral therapy or prophylaxis comprising administering a compound of any of claims 19-24 in a therapeutically or prophylactically effective amount to a subject in need of such therapy or prophylaxis.

### Claim 29

A method for use of magnesium alkoxide comprising reacting 9-(2hydroxypropyl)adenine (HPA) or 9-(2-hydroxyethyl)adenine (HEA), magnesium alkoxide, and protected p-toluenesulfonyloxymethylphosphonate.

### Claim 30 (depends on 29)

The method of claim 29 further comprising recovering PMPA or PMEA, respectively.

### Claim 31 (depends on 29)

The method of claim 29 wherein the phosphonate of the p-toluenesulfonyloxymethylphosphonate is protected by ethyl ester.

### Claim 32 (depends on 29)

The method of claim 29 wherein the alkoxide is a C1-C6 alkoxide.

### Claim 33 (depends on 32)

The method of claim 32 wherein the alkoxide is t-butyl or isopropyl oxide.
